2025
Utilizing Machine Learning to Improve Neutralization Potency of an HIV‑1 Antibody Targeting the gp41 N‑Heptad Repeat
Interrante M, Tang S, Kim S, Shanker V, Hie B, Bruun T, Wu W, Pak J, Fernandez D, Kim P. Utilizing Machine Learning to Improve Neutralization Potency of an HIV‑1 Antibody Targeting the gp41 N‑Heptad Repeat. ACS Chemical Biology 2025, 20: 1470-1480. PMID: 40540236, PMCID: PMC12281478, DOI: 10.1021/acschembio.5c00035.Peer-Reviewed Original ResearchConceptsN-heptad repeatNeutralization potencyHIV-1Gp41 N-heptad repeatTier 2 virusesMonoclonal antibodiesHIV-1 antibodiesVaccine development effortsEntry inhibitor enfuvirtideProtein language modelsHIV-1 gp41Potential vaccine targetsClinical efficacyVaccine targetsGp41AntibodiesMAbChallenge strainPotencyDiverse strainsSequence conservationZika virus vaccines and monoclonal antibodies: a priority agenda for research and development
Ostrowsky J, Katzelnick L, Bourne N, Barrett A, Thomas S, Diamond M, Beasley D, Harris E, Wilder-Smith A, Leighton T, Mehr A, Moua N, Ulrich A, Cehovin A, Fay P, Golding J, Moore K, Osterholm M, Lackritz E, Workgroup Z, Waldorf K, Barrett A, Beasley D, Bennie J, Bourne N, Brault A, Cehovin A, Coelho C, Diamond M, Emperador D, Faria N, Fay P, Golding J, Harris E, Hasanin N, Jaenisch T, Ko A, Lackritz E, Leighton T, Leo Y, Mehr A, Memish Z, Méndez-Rico J, Moore K, Mura M, Ng L, Osterholm M, Ostrowsky J, Peeling R, Rabe I, Salje H, Staples J, Thomas S, Ulrich A, Vanhomwegen J, Wongsawat J. Zika virus vaccines and monoclonal antibodies: a priority agenda for research and development. The Lancet Infectious Diseases 2025, 25: e402-e415. PMID: 40024262, PMCID: PMC12356332, DOI: 10.1016/s1473-3099(24)00750-3.Peer-Reviewed Original Research
2024
Vaccine-induced human monoclonal antibodies to PfRH5 show broadly neutralizing activity against P. falciparum clinical isolates
Thiam L, McHugh K, Ba A, Li R, Guo Y, Pouye M, Cisse A, Pipini D, Diallo F, Sene S, Patel S, Thiam A, Sadio B, Mbengue A, Vigan-Womas I, Sheng Z, Shapiro L, Draper S, Bei A. Vaccine-induced human monoclonal antibodies to PfRH5 show broadly neutralizing activity against P. falciparum clinical isolates. Npj Vaccines 2024, 9: 198. PMID: 39448626, PMCID: PMC11502735, DOI: 10.1038/s41541-024-00986-x.Peer-Reviewed Original ResearchP. falciparum clinical isolatesClinical isolatesNext-generation sequencingEarly clinical studiesDose-dependent inhibitionGrowth inhibition activitySingle B cellsOccurrence of novel mutationsNext-generation sequencing analysisBlood-stageNo significant differencePfRH5MAb combinationsNovel mutationsClinical studiesNeutralizing activityAntibody susceptibilityIgG responsesPre-clinicalGenotype/phenotype relationshipsMonoclonal antibodiesVaccine alleleGenetic diversitySignificant differenceMAbAntibody gene features associated with binding and functional activity in malaria vaccine-derived human mAbs
Coelho C, Marquez S, Nguemwo Tentokam B, Berhe A, Miura K, Rao V, Long C, Doumbo O, Sagara I, Healy S, Kleinstein S, Duffy P. Antibody gene features associated with binding and functional activity in malaria vaccine-derived human mAbs. Npj Vaccines 2024, 9: 144. PMID: 39127706, PMCID: PMC11316794, DOI: 10.1038/s41541-024-00929-6.Peer-Reviewed Original ResearchHuman monoclonal antibodyBlocking parasite transmissionMalaria vaccinePlasmodium antigensImpact of adjuvantsClonotypic diversityHuman mAbsAS01Adjuvant groupVaccine designMalariaMonoclonal antibodiesAdjuvant selectionFunctional antibodiesAlhydrogelMAbGermline sequencesAntibodiesAntibody repertoireFunctional mAbsFunctional activityAdjuvantCohortIGHV1VaccinePACIFIC-9: Phase III trial of durvalumab + oleclumab or monalizumab in unresectable stage III non-small-cell lung cancer
Barlesi F, Cho B, Goldberg S, Yoh K, Gelatti A, Mann H, Gopinathan A, Bielecka Z, Newton M, Aggarwal C. PACIFIC-9: Phase III trial of durvalumab + oleclumab or monalizumab in unresectable stage III non-small-cell lung cancer. Future Oncology 2024, 20: 2137-2147. PMID: 39023287, PMCID: PMC11508940, DOI: 10.1080/14796694.2024.2354160.Peer-Reviewed Original ResearchNon-small-cell lung cancerStage III non-small-cell lung cancerIII non-small-cell lung cancerPhase III trialsConcurrent chemoradiotherapyUnresectable stage III non-small-cell lung cancerLung cancerPhase III PACIFIC trialGlobal standard of careTargeting PD-L1Early-phase trialsStandard of carePACIFIC trialPD-L1Double-blindIII trialsPlacebo-ControlledDurvalumabMonalizumabOleclumabDisease progressionAntitumor activityMonoclonal antibodiesImmunotherapyMAbTransmission-reducing and -enhancing monoclonal antibodies against Plasmodium vivax gamete surface protein Pvs48/45
Bansal G, da Silva Araujo M, Cao Y, Shaffer E, Araujo J, Medeiros J, Hayashi C, Vinetz J, Kumar N. Transmission-reducing and -enhancing monoclonal antibodies against Plasmodium vivax gamete surface protein Pvs48/45. Infection And Immunity 2024, 92: e00374-23. PMID: 38289124, PMCID: PMC10929423, DOI: 10.1128/iai.00374-23.Peer-Reviewed Original ResearchDirect membrane feeding assaysTransmission-blocking vaccinesTransmission-blocking vaccine developmentMalaria transmission-blocking vaccineBlocked oocyst developmentInfectivity of gametocytesMale gamete fertilityMonoclonal antibodiesMembrane feeding assaysTransmission-blocking activityPvs48/45Activity of antibodiesNon-overlapping epitopesOocyst developmentPotential vaccine candidatesIndividual MAbsVaccine candidatesEffective immunogensChallenge modelMAbAntibodiesGametocytesEpitopesRecombinant fragmentsEnhanced activity
2019
1385. Mechanism-Based, In Vitro Inhibition of Mycobacterium abscessus: Assessing β-Lactam Therapy
Dousa K, Kurz S, Bethel C, Barnes M, Taracilla M, Selvaraju S, Jacobs M, Kreiswirth B, Kasperbauer S, Daley C, Bonomo R. 1385. Mechanism-Based, In Vitro Inhibition of Mycobacterium abscessus: Assessing β-Lactam Therapy. Open Forum Infectious Diseases 2019, 6: s503-s503. PMCID: PMC6809419, DOI: 10.1093/ofid/ofz360.1249.Peer-Reviewed Original ResearchB-lactamaseColony-forming unitsIn vitro susceptibility testingB-lactamase inhibitorsTherapeutically achievable concentrationsMab infectionRescue regimenMiddlebrook 7H9 brothVisible bacterial growthSusceptibility testingClinical isolatesImipenemBlaMabTreated patientsRelebactamAvibactamNontuberculous mycobacteriaB-lactamM. abscessusMAB isolatesTest agentsIn vitro inhibitionMAb complexesMAbMIC
1990
MHC-like molecules in some nonmammalian vertebrates can be detected by some cross-reactive monoclonal antibodies.
Kaufman J, Ferrone S, Flajnik M, Kilb M, Völk H, Parisot R. MHC-like molecules in some nonmammalian vertebrates can be detected by some cross-reactive monoclonal antibodies. The Journal Of Immunology 1990, 144: 2273-80. PMID: 1690241, DOI: 10.4049/jimmunol.144.6.2273.Peer-Reviewed Original ResearchConceptsMHC-like moleculesClass II moleculesClass IIII moleculesMHC moleculesNonmammalian vertebratesWestern blottingCross-reactivityCross-reactive monoclonal antibodiesHuman MHC moleculesMouse MHC moleculesVertebrate cellsSpleen cellsMAbs cross-reactedFlow cytometryMonoclonal antibodiesRadioactive bandsBlood cellsMAbBinding cellsLinear epitopesVertebratesXenoantiseraCross-reactive moleculesMice
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply